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Antisense therapy has been successful to skip targeted 
dystrophin exon with correction of frameshift and 
nonsense mutations of Duchenne muscular dystrophy 
(DMD). Systemic production of truncated but func-
tional dystrophin proteins has been achieved in animal 
models. Furthermore, phase I/II clinical trials in United 
Kingdom and the Netherlands have demonstrated dys-
trophin induction by local and systemic administrations 
of antisense oligomers. However, long-term efficacy and 
potential toxicity remain to be determined. The pres-
ent study examined 1-year systemic effect of phospho-
rodiamidate morpholino oligomers (PMO) treatment 
targeting mutated dystrophin exon 23 in mdx mice. 
PMO induced dystrophin expression dose-dependently 
and significantly improved skeletal muscle pathology 
and function with reduced creatine kinase (CK) lev-
els by a regimen of 60 mg/kg biweekly administration. 
This regimen induced <2% dystrophin expression in the 
heart, but improved cardiac functions demonstrated by 
hemodynamics analysis. The results suggest that low 
levels of dystrophin induction may be able to provide 
detectable benefit to cardiac muscle with limited myo-
pathy. Body weight, serum enzyme tests, and histology 
analysis showed no sign of toxicity in the mice treated 
with up to 1.5 g/kg PMO for 6 months. These results 
indicate that PMO could be used safely as effective drugs 
for long-term systemic treatment of DMD.
Received 14 September 2010; accepted 29 November 2010;  
published online 21 December 2010. doi:10.1038/mt.2010.288
IntroductIon
Mutations in the dystrophin gene cause two forms of muscular 
dystrophy, Duchenne and Becker muscular dystrophy (DMD and 
BMD). DMD is the most common lethal muscle disorder mainly 
resulting from nonsense and frameshift mutations preventing 
production of functional dystrophin protein. There is no effective 
treatment available. BMD is caused by in-frame mutations that 
typically create shortened, but partially functional dystrophin, 
leading to variable and often overt symptoms.1–3 The variability of 
disease phenotype among BMD population is the result of mul-
tiple factors affecting muscle functions. One of them is the func-
tionality of the truncated dystrophin due to mutations involving 
different region and the size of deletion. Sufficient preservation 
of functions by truncated (BMD-like) dystrophin underlies the 
principle of recombinant adeno-associated virus-mediated mini- 
and microdystrophin gene therapy.4 The same principle has now 
been utilized for the antisense oligomer-mediated exon skipping 
(antisense therapy). In antisense therapy, oligomers are specifi-
cally designed to bind target pre-mRNA sequence for exclusion 
of targeted exon(s). The removal of targeted exon(s) restores dys-
trophin reading frame, resulting in the expression of BMD-like 
dystrophins. Fortunately, most DMD mutations occur within the 
rod domain of the dystrophin gene which spans more than half 
the length of the protein, but seems to have limited functional 
importance.5,6 Antisense therapy therefore will be able to remove 
the mutated or additional exon(s) that disrupt the reading frame, 
thus restoring the expression of shortened forms of dystrophin 
protein retaining critical functions in most DMD patients.
Last 10 years have witnessed the significant progress in anti-
sense therapy for DMD.7–21 Early studies demonstrated the fea-
sibility of antisense oligonucleotides (AO) to remove targeted 
dystrophin exon in mouse and human cells.7,8,10 In 2003, AO was 
for the first time shown to be able to restore functional levels of 
dystrophin in the dystrophic mdx mice by intramuscular injec-
tions.12 Adeno-associated virus-mediated production of AO has 
been shown to be highly effective for targeted exon skipping both 
locally and systemically with long-term therapeutic effect.6 This 
approach thus has a strong advantage over synthetic AOs by elimi-
nating the need for repeated injections. However, establishing the 
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efficacy of adeno-associated virus-mediated gene delivery sys-
temically in human will likely take a prolonged period. In con-
trast, the effect of synthetic AOs on exon skipping is short-lived 
and short-term toxicity of most widely used AO chemistries has 
been established. This provides bases for regulatory authorities to 
approve synthetic AOs for clinical trials more willingly. As a result, 
clinical trials targeting human dystrophin exon 51 have been con-
ducted in the Europe to test the principle for treating a subgroup 
of DMD population.19,20 Since then, AO-mediated exon skipping 
with synthetic AOs has progressed into one of the most promising 
experimental therapy for DMD. Systemic efficacy with functional 
improvement has been demonstrated in both dystrophic mouse 
and dog models.13,14,18 The use of peptides and cationic polymers 
for enhanced delivery of phosphorodiamidate morpholino oli-
gomers (PMO) has achieved restoration of dystrophin expres-
sion to near normal levels in body-wide skeletal muscles and to 
a less degree in the cardiac muscle.15,16 High level expression of 
the restored dystrophin improved functions of both dystrophic 
skeletal and cardiac muscles significantly. However, increased tox-
icity and potential immune response to the cationic peptide and 
polymers demand a more thorough preclinical tests before these 
modified AOs can be trialed in clinics. Therefore, clinical trials for 
exon skipping are currently being limited to the use of unmodified 
PMO and 2’-O-methyl phosphorothioate (2OMePS) chemistries. 
Completed phase I clinical trials by local muscle injections tar-
geting exon 51 reported the significant amount of targeted exon 
skipping and dystrophin production in nearly all treated muscles 
with both 2OMePS and PMO.19,20 More recently, similar to that 
observed in the animal models, systemic treatment of DMD 
patients with PMO was reported to induce detectable amount 
of dystrophin protein in sampled skeletal muscles of all patients, 
although considerable variation in skipping efficiency was also 
clearly observed within the trial population.21
AO drugs act on pre-mRNA of dystrophin for the removal 
of targeted exon. The therapeutic effect is therefore short-lived 
with single administration. Previous investigations suggested 
that the effect of dystrophin induction after single intrave-
nous (i.v.) injection of PMO in mdx mice lasted ~2 months.12 
Antisense therapy for DMD requires life-long administration 
and the capacity of the drugs to maintain functional levels of 
dystrophin with tolerable toxicity. It is therefore important to 
understand whether therapeutic levels of dystrophin can be 
maintained by regular injections for a prolonged time. However, 
nearly all studies of i.v. AO administrations in animal mod-
els have so far limited to a short-time period. It is especially 
important as delivery efficiency of both antisense chemistries, 
2OMePS and PMO, is apparently related to the state and degree 
of muscle degeneration and regeneration, being less effective in 
normal muscles when compared to degenerative muscles. This 
raises the concern that regular injections of AO, especially at 
low dosage might not be able to halt the cycles of degenera-
tion when only a limited amount of dystrophin is produced in 
only a proportion of muscle fibers. Efficiency of exon skipping 
and dystrophin production in cardiac muscle with unmodified 
2OMePS and PMO is significantly lower than that in skeletal 
muscles. This also causes concern that restoration of higher lev-
els of dystrophin in skeletal muscles may exacerbate the failure 
of heart function if dystrophin expression cannot be effectively 
restored in cardiac muscle.22
In the present study, we investigated a long-term dosage effect 
of PMO treatment in the dystrophic mdx mice. We demonstrated 
that PMO was able to induce effective targeted exon skipping 
and dystrophin expression in all muscles dose-dependently dur-
ing 1-year treatment although accumulative effect was limited. 
Higher dosages of PMO were associated with increasing levels of 
dystrophin expression and improvement of muscle pathology and 
functions without detectable toxicity.
results
one-year i.v. administration of 15 mg/kg PMo 
revealed no significant improvement in muscle 
pathology
We have earlier shown that a single i.v. injection of 15 mg/kg PMO 
targeting mouse dystrophin exon 23 was able to induce lower, 
but detectable levels of dystrophin expression.17 As the half-life of 
PMO-induced dystrophin expression was reported to be about 2 
months, we hypothesized that repeated administration with this 
dose of PMO biweekly might lead to higher levels of dystrophin 
induction, sufficient to achieve therapeutic significance. To test 
this, we treated the mdx mice with 15 mg/kg PMO biweekly for 1 
year. Two weeks after the last injections, skeletal and cardiac mus-
cles were examined. The revertant fibers of <1.5% were detected 
in all muscles from control mdx mice. Dystrophin positive fibers 
increased to up to 5% in all the skeletal muscles from the PMO-
treated mice, although a small number of fibers with weak par-
tial dystrophin positive signal was also observed (Figure 1a). The 
maximum amount of dystrophin protein examined by western 
blots accounted for 2.6% of normal level in any skeletal muscles 
(Figure 1c). This effect was therefore similar to that observed in 
muscles after single injection of 15 mg/kg PMO, suggesting no sig-
nificant accumulation in exon-skipping effect by the dosing regi-
men. No clear difference in pathology and variation in fiber size of 
skeletal muscle were observed (Figures 1e and 2a). Sirius staining 
showed no clear reduction in staining intensity for collagens in the 
treated muscles when compared to the controls (Supplementary 
Figure S1). Consistently, the function of the skeletal muscles mea-
sured by grip-force generation were only marginally improved with 
no difference in creatine kinase (CK) levels in the treated group 
when compared to the untreated control mdx mice (Figure 2b,c). 
No dystrophin expression and specific exon 23 skipping were 
detected in the cardiac muscle and measurement for cardiac func-
tions revealed no significant difference from the untreated control 
mdx mice (Figures 1 and 3; Tables 1 and 2). Body weight, serum 
enzyme tests, and histological examination of lung, kidney, and 
liver showed no differences between the treated and the untreated 
control mdx mice (Figure 2).
one-year i.v. administration of 60 mg/kg PMo 
significantly improved skeletal muscle pathology
Earlier study showed that single i.v. injection of 2 mg PMO per 
adult mdx mice (~60–80 mg/kg) was able to induce dystrophin 
expression in body-wide skeletal muscles of mdx mice.14 We 
therefore examined long-term effect of 60 mg/kg PMO by regular 
biweekly i.v. injections. Skeletal muscles after 1-year treatment saw 
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significant induction of targeted exon 23 skipping and dystrophin 
expression. The levels of exon 23 skipping by reverse transcription-
PCR (RT-PCR) ranged from barely detectable to 40% in skeletal 
muscles (Figure 1b). Dystrophin positive fibers, with highly vari-
able intensity, were counted from 10 to 50% in skeletal muscles 
examined (Figure 1a). Such variation was seen between different 
muscles as well as within the same type of muscles from different 
mdx mice. Variation in exon-skipping efficiency was also demon-
strated by western blots with the levels of dystrophin protein up 
to 17.1% (Figure 1c). The treated mice showed clearly detectable 
improvement in skeletal muscle pathology with reduced central 
nucleation (Figure 1e) and a more homogenous population of 
fibers in size (Figure 2a). Sirius staining showed a clear reduction 
in the intensity for collagens in the treated skeletal muscles when 
compared to the controls (Supplementary Figure S1). CK levels 
in the treated mice were significantly reduced when compared to 
the untreated control mdx mice, but remained higher than that 
of normal C57BL/6 mice (Figure 2b). Significant improvement 
was also detected in muscle functions with grip-force generation 
(Figure 2c). The results suggest that this dosage of PMO treatment 
can achieve measurable therapeutic outcome in skeletal muscles 
without detectable toxicity.
Improvement in cardiac functions after 1-year 
treatment of 60 mg/kg PMo
The efficiency of exon skipping in the cardiac muscle was consider-
ably lower than that in skeletal muscles after the 1-year PMO treat-
ment. Less than 5% dystrophin positive fibers, most of them with 








Control 9.29 ± 0.62 9.10 ± 2.01 11.94 ± 0.41
15 mg/kg PMO 8.14 ± 0.76 10.16 ± 0.84 11.89 ± 2.62
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Figure 1 restoration of dystrophin expression after 1-year intra-
venous (i.v.) treatment of 15 or 60 mg/kg phosphorodiamidate 
morpholino oligomers (PMo). (a) Detection of dystrophin by immu-
nohistochemistry with rabbit polyclonal antibody P7 against dystrophin. 
Blue nuclear staining with DAPI. (b) Detection of exon 23 skipping 
in muscles by reverse transcription-PCR (RT-PCR). Lane 1 size marker. 
(c) Western blot showed levels of dystrophin expression in muscles 
[10 µg total protein loaded from tibialis anterior (TA) muscle of C57BL/6 
mouse; 50 µg total protein loaded from untreated or PMO-treated mdx 
mice]. C57-TA, TA muscle from normal C57BL/6 mouse; Cont-TA, TA 
muscle from untreated mdx mouse. 15 or 60 mg/kg, the muscles from 
15 or 60 mg/kg PMO-treated mdx mice. The samples from two different 
mdx mice treated with 60 mg/kg PMO were shown. (d) α-Actin as load-
ing controls. (e) The percentage of non-centranucleated muscle fibers. 
Control, muscles from untreated mdx mouse. (n = 10; #P ≤ 0.05 com-






















































































Figure 2 examination of pathology, serum, and skeletal muscle 
function after 1-year treatment of 15 and 60 mg/kg phospho-
rodiamidate morpholino oligomers (PMo). (a) Histology [hema-
toxylin and eosin (H&E) staining] of tibialis anterior (TA), diaphragm, 
liver, and kidney from the normal C57BL/6 mice, untreated mdx mice 
(control), 15 or 60 mg/kg PMO-treated mdx mice (15 mg/kg, 60 mg/
kg). (b) The levels of serum enzymes. Creatine kinase (KU/l), creati-
nine (mg/l), urea nitrogen (mg/ml), total bilirubin (mg/l), direct bili-
rubin (mg/dl), alanine transaminase (ALT) (U/dl), alkaline phosphatase 
(ALP) (U/dl), and γ-glutamyltransferase (GGT) (U/l). A significant 
reduction in creatine kinase levels was observed in mdx mice treated 
with 60 mg/kg PMO when compared with untreated mdx mice. (c) 
Grip strength measurement. Significant improvement was observed 
in the mice after treatment with 60 mg/kg PMO. KGF, kilogram force. 
(n = 10; *P ≤ 0.05 compared with C57BL/6 mice; #P ≤ 0.05 compared 
with untreated mdx mice. Two-tailed t-test). Final mean body weight: 
C57BL/6, 31.3 ± 0.8 g; untreated mdx, 34.1 ± 2.0; 15 mg/kg PMO-
treated mdx, 31.8 ± 2.4 g; 60 mg/kg PMO-treated mdx, 33.7 ± 1.6 g. 
PMO, phosphorodiamidate morpholino oligomers.
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the cardiac muscle (Figure 1a). The levels of dystrophin protein 
were only up to 2% by western blot in all heart of treated mice 
(Figure 1c). To determine the potential effect of the treatment with 
such limited protein induction on cardiac functions, we examined 
the cardiac muscles first by ultra-high frequency echocardiogra-
phy. No significant difference in histology and ventricular func-
tion of the heart was identified between the treated group and the 
untreated control mice. We further examined the heart functions 
of the PMO-treated mdx mice by hemodynamics analysis under 
dobutamine stress in comparison with the untreated control mdx 
mice and normal C57BL/6 mice. This analysis has been reported 
to be highly sensitive to distinguish the degree of underline func-
tional defects and to demonstrate potential therapeutic effect in 
the cardiac muscle of the mdx mice.15 The untreated control mdx 
mice showed clear deficits of cardiac functions with reduction in 
the stoke volume, cardiac output, maximum upstroke velocity (dV/
dtmax), ventricular isovolumic relaxation time constant (τ), ejection 
fraction, and increase of minimum upstroke velocity (dV/dtmin), 
when compared to the normal C57BL/6 mice (Table 1). One-year 
treatment of 60 mg/kg PMO slightly improved the stoke volume, 
cardiac output, ventricular isovolumic relaxation time constant (τ), 
and ejection fraction, but the changes were not statistically signifi-
cant. Significant improvement was however, revealed in the maxi-
mum and minimum upstroke velocity (dV/dtmax and dV/dtmin) 
(Table 1). Under dobutamine stress, the untreated control mdx 
mice showed significant cardiac dysfunctions, including decreases 
in stoke volume, cardiac output, end-diastolic volume, end-systolic 
pressure, dp/dtmax, dV/dtmax, ejection fraction, and an increase in 
dp/dtmin, dV/dtmin (Figure 3 and Table 2). Under the same stress 
condition, the 60 mg/kg PMO-treated mdx mice showed improved 
cardiac functions, especially in stoke volume, cardiac output, end-
diastolic volume, end-systolic pressure, dp/dtmax, dV/dtmax, dV/
dtmin, and ejection fraction (Figure 3 and Table 2).
repeated high-dose treatments further enhanced the 
exon-skipping efficiency and skeletal muscle function
The dose-dependent short- and long-term exon-skipping effect and 
functional improvement prompted us to examine the potential of 
PMO treatment with two higher doses of 300 mg/kg and 1.5 g/ kg. 
Six months of biweekly treatment with PMO at 300 mg/kg were 
able to achieve dystrophin expression in >50% fibers in body-wide 
skeletal muscles (Figure 4a). The levels of truncated dystrophin 
mRNA ranged from 25 to 40 % (Figure 4b). Western blot detected 
>15% of normal levels of dystrophin protein in all skeletal muscles 
(Figure 4c). Muscle pathology was clearly improved with none to 
only a few individual degenerating fibers detected in any skel-
etal muscles examined (Figure 5a). The fibers within the same 
muscle became highly uniform and with no clear inflammatory 
cell infiltrations. Sirius staining showed a very clear reduction in 
the intensity for collagens in the treated skeletal muscles when 
compared to the controls and the lower dose-treated mdx mice 
(Supplementary Figure S1). Consistently, the CK levels were 
significantly reduced when compared to those untreated control 
mice and the mice with lower doses of PMO treatment (Figures 
2b and 5b). Muscle functions as measured by grip-force genera-
tion were significantly improved (Figure 5c). Dystrophin expres-
sion with strong signal was also detected in a small proportion 
of cardiac muscle fibers and the amount of dystrophin protein 
became detectable although still <4% in all heart of the treated 
mice (Figure 4c).
Increasing the dose of PMO to 1.5 g/kg saw further improve-
ment of dystrophin induction in all muscles. Nearly 100% fibers in 
all skeletal muscles expressed dystrophin by immunohistochem-
istry with the levels of the protein reaching 25–50% (Figure 4a,c). 
This level of dystrophin expression was associated with significant 
improvement in muscle function with the grip force reaching the 
strength near to the normal C57BL/6 mice (Figure 5c). CK levels 
reduced dramatically compared to those untreated control mice 
(Figure 5b). All skeletal muscle fibers became highly uniform in 
size, and degenerating fibers and inflammatory infiltrates were 
absent in all muscles (Figure 5a). More than 40% of cardiac mus-
cle fibers expressed dystrophin although most of them had weak 
signal for the protein. During the 6-month treatment with these 
two high dosages, the mice showed no sign of abnormal behavior 
and change in body weight. No pathological change of the liver, 





































































































































































Figure 3 cardiac functions in the mdx mice treated with 15 or 
60 mg/kg phosphorodiamidate morpholino oligomers (PMo) (1 
year) by hemodynamics at 15 minutes after dobutamine challenges. 
Significant improvement was observed in (a) stroke volume, (b)  cardiac 
output, (c) end-systolic pressure, (d) ejection fraction, (e) dp/dtmax, 
(f) dp/dtmin, (g) dV/dtmax, (h) dV/dtmin. (1) Age-matched normal C57BL/6 
mice; (2) age-matched untreated mdx mice; (3) 1-year 15 mg/kg PMO-
treated mdx mice; (4) 1-year 60 mg/kg PMO-treated mdx mice. (n = 10; 
*P ≤ 0.05 in comparison with C57BL/6 mice; #P ≤ 0.05 in comparison 
with untreated mdx mice. Two-tailed t-test).
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and serum tests for urea nitrogen, total bilirubin, direct bilirubin, 
alkaline phosphatase, and γ-glutamyltransferase. (Figure 5a,b).
dIscussIon
Since the first demonstration of therapeutic effect in vivo in DMD 
animal model of mdx mice, AO-mediated exon skipping has pro-
gressed into one of the most promising experimental therapies. 
Short-term systemic administration of antisense PMO is able to 
achieve functional levels of dystrophin expression in both mouse 
and dog models of DMD.14,18 Data from the ongoing clinical trial 
of PMO targeting exon 51 has confirmed systemically induced 
dystrophin expression in muscles of DMD boys after weekly 
treatment.21 However, effective exon skipping for DMD requires 
life-long administration and the capacity of antisense drugs to 
maintain functional levels of dystrophin with tolerable toxicity. In 
this study, we demonstrated that systemically administrated AO 
as PMO was indeed able to induce effective targeted exon skipping 
and dystrophin expression in all muscles in a dose- dependent man-
ner for 1 year in mdx mice. Bodyweight, appearance, and behavior 
of the treated animal with all dosages were not significantly dif-
ferent from the control groups during the period of 1-year treat-
ment. Serum tests and histology analysis showed no pathological 
changes in the liver, kidney and lung. Lack of toxicity was further 
demonstrated in the mice treated with up to 1.5 g/ kg PMO for 6 
months. These results together suggest that PMO treatment can 
achieve long-term therapeutic effects and is well tolerated.
table 1 Baseline hemodynamic data
 c57 control 15 mg/kg PMo 60 mg/kg PMo
Heart rate (bpm) 405.3 ± 35.5 406.1 ± 32.4 394.7 ± 40.9 393.8 ± 18.0
Stoke volume (RVU) 4.7 ± 0.4 4.0 ± 0.3 4.2 ± 0.9 5.1 ± 0.6
Cardiac output (RVU/min) 1,909.4 ± 239.2 1,600.9 ± 172.0 1,536.8 ± 272.8 1,938.8 ± 301.8
End-systolic volume (RVU) 13.8 ± 0.8 14.8 ± 0.7 15.0 ± 1.0 14.3 ± 0.8
End-diastolic volume (RVU) 17.4 ± 0.6 17.8 ± 0.7 18.5 ± 0.6 18.5 ± 0.8
End-systolic pressure (mm Hg) 90.0 ± 2.1 88.4 ± 3.0 99.8 ± 8.0 98.1 ± 4.6
End-diastolic pressure (mm Hg) 7.5 ± 1.1 7.8 ± 1.0 7.6 ± 2.4 8.1 ± 1.9
Arterial elastance (mm Hg/RVU) 20.6 ± 2.1 20.7 ± 1.5 20.8 ± 2.1 20.7 ± 2.8
dp/dtmax (mm Hg/sec) 7,807.6 ± 828.8 7,815.3 ± 901.1 7,828.2 ± 1,139.0 7,606.0 ± 152.1
dp/dtmin (mm Hg/sec) −7,066.1 ± 877.4 −7,291.0 ± 719.2 −7,775.5 ± 1,410.7 −6,947.2 ± 645.7
dV/dtmax (RVU/sec) 213.5 ± 29.3 165.5 ± 11.0 221.3 ± 33.9 225.5 ± 6.4#
dV/dtmin (RVU/sec) −202.2 ± 25.5 −130.6 ± 10.1* −215.7 ± 37.3# −242.5 ± 28.9#
τ (ms) 9.5 ± 1.6 8.9 ± 0.6 9.2 ± 0.7 9.3 ± 1.1
Ejection fraction (%) 26.5 ± 2.5 21.7 ± 1.1 22.4 ± 4.7 26.5 ± 2.4
Abbreviations: 15 mg/kg PMO, 1-year 15 mg/kg PMO-treated mdx mice; 60 mg/kg PMO, 1-year 60 mg/kg PMO-treated mdx mice; C57, normal C57BL/6 mice; control, 
untreated mdx mice; PMO, phosphorodiamidate morpholino oligomers; RVU, relative volume units.
n = 10; *P ≤ 0.05 in comparison with C57BL/6 mice; #P ≤ 0.05 in comparison with untreated mdx mice. Two-tailed t-test.
table 2 Hemodynamic parameters 15 minutes after dobutamine infusion
 c57 control 15 mg/kg PMo 60 mg/kg PMo
Heart rate (bpm) 410.1 ± 30.5 349.2 ± 12.3 362.5 ± 31.5 353.0 ± 7.0
Stoke volume (RVU) 5.4 ± 0.6 3.6 ± 0.6* 4.9 ± 0.5 6.2 ± 0.9#
Cardiac output (RVU/min) 2,135.2 ± 218.6 1,332.2 ± 228.5* 1,428.2 ± 197.5 2,211.0 ± 355.4#
End-systolic volume (RVU) 13.4 ± 0.8 14.3 ± 0.9 16.8 ± 1.3 12.6 ± 0.8
End-diastolic volume (RVU) 18.8 ± 0.6 16.1 ± 0.7* 20.3 ± 1.0# 20.8 ± 2.0#
End-systolic pressure (mm Hg) 88.4 ± 4.6 63.7 ± 4.1* 77.4 ± 6.2 79.7 ± 4.3#
End-diastolic pressure (mm Hg) 6.7 ± 1.0 6.8 ± 1.7 5.9 ± 5.1 6.3 ± 1.9
dp/dtmax (mm Hg/sec) 8,659.9 ± 728.7 6,020.3 ± 532.0* 6,627.0 ± 1,503.8 7,905.2 ± 490.8#
dp/dtmin (mm Hg/sec) −7,212.7 ± 631.3 −5,111.1 ± 519.9* −5,713.0 ± 316.5 −5,741.0 ± 644.3
dV/dtmax (RVU/sec) 232.8 ± 39.9 145.5 ± 20.1* 255.3 ± 35.8# 280.0 ± 32.6#
dV/dtmin (RVU/sec) −240.0 ± 8.2 −163.7 ± 4.3* −248.3 ± 27.5# −268.5 ± 21.4#
τ (ms) 8.2 ± 0.7 8.0 ± 1.0 9.1 ± 2.0 8.1 ± 0.9
Ejection fraction (%) 29.9 ± 2.9 20.9 ± 2.9* 23.4 ± 2.7 33.2 ± 3.9#
Abbreviations: 15 mg/kg PMO, 1-year 15 mg/kg PMO-treated mdx mice; 60 mg/kg PMO, 1-year 60 mg/kg PMO-treated mdx mice; C57, normal C57BL/6 mice; control, 
untreated mdx mice; PMO, phosphorodiamidate morpholino oligomers; RVU, relative volume units.
n = 10; *P ≤ 0.05 in comparison with C57BL/6 mice; #P ≤ 0.05 in comparison with untreated mdx mice. Two-tailed t-test.
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Appropriate dosage of AO drug given systemically is criti-
cal for achieving long-term therapeutic efficacy to DMD. Part 
of the present study aimed to assess the potential therapeutic 
dosage and accumulative effect with long-term regular admin-
istration of PMO. Our results showed that targeted exon skip-
ping and expression of dystrophin can be detected at the lowest 
dose of 15 mg/kg with biweekly i.v. injections although this 
dosage is apparently insufficient to achieve significant levels 
of dystrophin induction and therapeutic effect. When 60 mg/
kg PMO was given biweekly, exon 23 skipping and dystrophin 
expression were clearly demonstrated in all muscles. Significant 
improvement in muscle pathology was indicated by reductions 
in muscle damage, central-nucleated fibers, collagen deposit, 
and serum CK levels. Furthermore, improvement in muscle 
function was recorded by grip-force measurement. This result 
suggests that 60 mg/kg PMO was able to achieve clearly detect-
able therapeutic effect with measurable improvement in muscle 
functions in the dystrophic mdx mouse. The result is consis-
tent to our early observation that a similar dose of PMO with 7 
weekly treatments is able to achieve clearly detectable improve-
ment in muscle functions.14 Therefore, this dosage could be 
considered as a useful reference to a treatment regimen aim-
ing to achieve efficacy with PMO-mediated exon skipping 
systemically.
However, caution needs to be exercised when the data from 
this study are extrapolated for the purpose of the treatment of 
DMD. Efficacy of antisense therapy to treat individual DMD 
patient, depends on many other factors, especially the efficiency 
of individual antisense drug and the functionality of the trun-
cated dystrophin determined mainly by the location of mutations 
and size of deletions. Both determinants are difficult or yet to be 
defined for targeting most human dystrophin exons. However, the 
following two factors are likely to affect our consideration for the 
reference value of effective dosage observed in the mdx mice. First, 
it is most probable that a truncated dystrophin lacking only exon 
23 produced in the mdx mice muscles will retain better function 
than most truncated dystrophins expected from DMD patients 
after exon skipping. Second, the PMOE23+7-18 used in the pres-
ent study has been optimized and tested extensively with high 
degree efficiency in both cell culture and in vivo. This is in con-
trast to the lack of appropriate system to verify exon-skipping effi-
ciency in vivo for AO drugs targeting human dystrophin exon. It is 
therefore likely that a considerable higher dosage may be required 
to achieve clearly measurable therapeutic outcome with most AO 
drugs targeting human dystrophin exons in clinic providing that 











































Figure 4 restoration of dystrophin expression in the mdx mice after 
6 months intravenous (i.v.) treatment with phosphorodiamidate 
morpholino oligomers (PMo) (300 mg/kg or 1.5 g/kg biweekly). 
(a) Detection of dystrophin by immunohistochemistry with rabbit poly-
clonal antibody P7. Blue nuclear staining with DAPI. (b) Detection of 
exon 23 skipping in muscles by reverse transcription-PCR (RT-PCR). Lane 
1, size marker. (c) Western blot for dystrophin expression [25 µg total 
protein loaded from tibialis anterior (TA) muscle of C57BL/6 mouse; 50 µg 
total protein loaded from untreated or treated mdx mice]. C57-TA, TA 
muscle from normal C57BL/6 mouse; Cont-TA, TA muscle from untreated 
mdx mouse. 300 mg/kg, 300 mg/kg PMO-treated mdx mice. 1.5 g/kg 





























































































Figure 5 examination of pathology, serum, and skeletal muscle func-
tion after 6 months treatment with 300 mg/kg and 1.5 g/kg phospho-
rodiamidate morpholino oligomers (PMo). (a) Histology [hematoxylin 
and eosin (H&E) staining] of tibialis anterior (TA), diaphragm, and kid-
ney from untreated (control), 300 mg/kg and 1.5 g/kg PMO-treated mdx 
mice (300 mg/kg, 1.5 g/kg). (b) The levels of serum enzymes. Creatine 
kinase (KU/l), creatinine (mg/l), urea nitrogen (mg/ml), total bilirubin 
(mg/l), direct bilirubin (mg/dl), alanine transaminase (ALT) (U/dl), alka-
line phosphatase (ALP) (U/dl), and γ-glutamyltransferase (GGT) (U/l). (c) 
Grip strength tests. Significant improvement was observed in the mdx 
mice treated with 300 mg/kg and 1.5 g/kg PMO. KGF, kilogram force. 
(n = 10; *P ≤ 0.05 in comparison with C57BL/6 mice; #P ≤ 0.05 in com-
parison with untreated mdx mice. Two-tailed t-test).
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basis. When the outcome of the ongoing clinical trials becomes 
available, it might be possible to establish a relative efficiency of 
new AO drugs targeting different exons with the AO on trial as the 
control. This can be achieved by testing two AOs together in the 
same cell culture and/or in the same animal model of humanized 
mdx mice. This together with our understanding of functionality 
of individual truncated dystrophin would provide a more accurate 
assessment for a dosing to achieve efficacy in clinics.
DMD mutations affect the expression of dystrophin in all mus-
cles including cardiac muscle. While defects in cardiac functions 
as a result of dystrophin deficiency is not prominent in the early 
stage of disease manifestation, failures of cardiac function, and the 
respiratory system are the leading causes of lethality in later stage 
of disease progression. Thus, restoration of functional levels of dys-
trophin to prevent deterioration in cardiac functions constitutes 
one of the critical aims for the exon skipping to be effective therapy. 
Furthermore, as DMD patients live longer due to improved mul-
tidisciplinary patient care, rescuing dystrophin expression in car-
diac muscle becomes more critical for their longevity and quality of 
life.23–27 Early studies however, revealed that the efficiency of anti-
sense oligomer-induced exon skipping was significantly (several 
folds) lower in cardiac muscle than in skeletal muscles. Systemic 
PMO treatment at the doses <300 mg/kg produced only barely 
detectable (<5% normal levels) dystrophin in the cardiac  muscle.14,17 
This lower efficiency of exon skipping becomes one of the major 
concerns for the therapy to be effective to DMD patients. The 
results from the present study confirmed that the cardiac muscle 
is much more resistant to PMO-mediated exon skipping. Only 2% 
or less normal levels of dystrophin expression were detected in the 
heart after 1-year i.v. injections of 60 mg/kg PMO. The result also 
indicates a limited accumulative exon-skipping effect in the cardiac 
muscle with the biweekly treatment regimen. Nevertheless, func-
tional improvement, although limited, was clearly demonstrated 
by the hemodynamics analysis. This result suggests that low levels 
of dystrophin induction may be able to provide benefit to cardiac 
functions although other factors such as improved functions in 
skeletal muscle especially the diaphragm could also be involved.22 
However, it is also possible that such low levels of dystrophin induc-
tion, being sufficient to provide improvement to the mildly affected 
cardiac muscle of the mdx mice, may not be sufficient to improve 
functions of severely affected cardiac muscles in DMD patients.
The half-life of AO-induced dystrophin protein has been esti-
mated to be about 2 months although it is not clear whether this is 
the result of protein stability or the sustained effect of AO within the 
fibers. Previous studies observed significant accumulation in dystro-
phin protein by short-term weekly or daily injections.14 Therefore, 
we expected that the levels of dystrophin after 1-year biweekly 
injections would be significantly higher than that after single injec-
tion when the same dose of PMO is used. Unexpectedly, the results 
showed that the long-term accumulative effect of PMO was limited. 
The mechanism(s) is not understood, but the following factors may 
be involved. Firstly, a biweekly regimen will certainly have less accu-
mulative effect than a weekly regimen. Perhaps more importantly, 
the dependence of unmodified PMO on the increased membrane 
permeability for effective delivery may constitute another possible 
explanation. Since the efficiency of PMO relies heavily on perme-
ability of muscle fibers and dystrophic muscles undergo cycles of 
degeneration and regeneration, the initial a few doses of PMO 
would achieve higher efficiency through the fraction of muscle 
fibers with higher permeability. However, such fiber population 
decreases gradually and most muscle fibers become less permeable 
to PMO eventually, leading to a diminishing delivery efficiency, 
thus accumulative effect. This hypothesis is consistent with the fact 
that normal muscles are resistant to PMO delivery.14 While the lim-
ited accumulative effect may indicate the improvement in muscle 
membrane permeability after the treatment, it also suggests that 
long-term efficiency in exon skipping with PMO and 2OMePS may 
be difficult to exceed that achieved by a single dose of AO.
MaterIals and MetHods
Animals, oligonucleotides, and in vivo delivery methods. Ten mdx mice 
and C57BL/6 mice aged 4–5 weeks were used in each group. Experiments 
were approved by IACUC Carolinas Medical Center (protocol # 01-08-
06A for breeding of mdx mice; protocol # 01-08-07A for PMO oligonu-
cleotide therapy for DMD). The PMO (+07-18) (5′-GGCCAAACCTCG 
GCTTACCTGAAAT-3′) against the boundary sequences of exon and 
intron 23 of dystrophin gene (PMO) were used (Gene Tools, Philomath, 
OR). For i.v. administration, PMO was used in 100-µl saline by retro-
orbital injections. Same volume of saline was used in control mice. Mice 
were killed at desired time points, and muscles were snap-frozen in liquid 
nitrogen-cooled isopentane and stored at −80 °C.
Antibodies and immunohistochemistry. Sections of 6 µm were cut from 
at least two-thirds of muscle length of tibialis anterior, quadriceps, biceps, 
and gastrocnemius at 100 µm intervals and at least 10 levels from all other 
muscles including heart, diaphragm, intercostals, and abdominal muscles 
at 100 µm intervals. The intervening muscle sections were collected either 
for western blot and RT-PCR analysis. The serial sections were stained with 
rabbit polyclonal antibody P7 against dystrophin sequences from amino 
acid 2847 to amino acid 2990.12–14 The primary antibody was detected by 
goat-anti-rabbit immunoglobulin Gs Alexa 594 (Invitrogen, Eugene, OR). 
Sections were also stained with hematoxylin and eosin or picrosirius red 
solution for histological and collagen assessment.
Protein extraction and western blot. The collected sections were ground 
into powder and lysed with 200-µl protein extraction buffer as described 
previously.15,16 The protein concentration was quantified by Protein Assay 
Kit (Bio-Rad, Hercules, CA). Proteins were loaded onto a 4–15% Tris–HCL 
gradient gel. Samples were electrophoresed overnight at 10 mA at 4 °C and 
blotted onto nitrocellulose membrane overnight at 50 V. The membrane 
was then washed and blocked with 5% skimmed milk and probed with 
monoclonal antibody NCL-DYS1 against dystrophin rod domain (Vector 
Labs, Burlingame, CA) overnight. The bound primary antibody was 
detected by horseradish peroxidase-conjugated goat anti-mouse immu-
noglobulin G and ECL Western Blotting Analysis System (Perkin Elmer, 
Waltham, MA). The intensity of the bands obtained from the oligomer-
treated mice muscles was measured and compared with that from normal 
muscles of C57BL/6 mice (NIH ImageJ 1.42 software).
RNA extraction and RT-PCR. The collected sections were homogenized 
in TRIzol (Invitrogen) by using an Ultra-Turrax homogenizer (Janke and 
Kunkel, Staufen, Germany). Total RNA was then extracted and 100 ng of 
RNA template was used for a 50-ml RT-PCR with RT-PCR Master Mix 
(USB, Cleveland,OH). The primer sequences for the RT-PCR were Ex20Fo 
5′-AGAATTCTGCCAATTGCTGAG-3′ and Ex26Ro 5′-TTCTTCAGCT 
TGTGTCATCC-3′ for amplification of mRNA from exons 20 to 26. A total 
of 40 cycles were carried out for the RT-PCR. Bands with the expected 
size for the transcript with exon 23 deleted were extracted and sequenced. 
The intensity of the bands was measured with the NIH ImageJ 1.42 and 
percentage of exon skipping was calculated with the intensity of the two 
bands representing both exon 23 unskipped and skipped as 100%.
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Cardiac imaging. Mice were placed in an induction chamber with 4% 
isoflurane mixed with 100% oxygen. The mouse was monitored for heart 
rate (350–550 bpm) and rectal temperature (36.5–37.5 °C) throughout the 
procedure. Two dimensional, M-mode, and spectral Doppler Imaging was 
performed using the VisualSonics Vevo 770 ultrasound system with the 
RMV 707 transducer (VisualSonics, Toronto, Ontario, Canada). At the 
completion of the scanning, the mouse was removed from anesthesia and 
allowed to wake up prior to returning to the colony.
Grip strength test. Grip strength was assessed using grip strength meter 
consisting of horizontal forelimb mesh and an angled hind limb mesh 
(Columbus Instruments, Columbus OH). Five successful hindlimb and 
forelimb strength measurements within 2 minutes were recorded, and data 
was normalized to body weight and expressed as kilogram force.
Measurement of serum CK and other components. Mouse blood was 
taken immediately after cervical dislocation and centrifuged at 1,500 r.p.m. 
for 3 minutes. Serum was separated and stored at −80 °C. The level of 
serum components was determined by Charles Riverside Laboratories 
(Columbia, MO).
In vivo cardiac hemodynamics. Hemodynamics analysis on the treated 
and untreated mdx as well as the C57BL/6 mice were performed using 
conductance micromanometry according to previously published meth-
ods.28–30 Briefly, the mice were anesthetized by inhalation of 1% isoflou-
rane and 99% oxygen. The mice were then ventilated at 120 strokes/
minute with a rodent ventilator (Harvard Instruments, Holliston, MA) 
and kept on a warm pat to stabilize the body temperature at 37° C. A 1.4 
F high-fidelity micromanometer catheter (Millar Instruments, Houston, 
TX) was inserted into the left ventricle through carotid artery under 
continuous hemodynamic monitoring. Following collection of baseline 
hemodynamic data, dobutamine was infused at a rate of 6.5 µg/g/min for 
3 minutes through the jugular vein. Pressure-volume loops data were col-
lected online at 500 Hz. Hemodynamic parameters were analyzed with 
PVAN3.3 software (Millar Instruments).
suPPleMentarY MaterIal
Figure S1. Examination of collagen deposition in muscles by picro-
sirius staining.
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